Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06140329 · ClinicalTrials.gov registry record
Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation
A clinical trial, sponsored by PYC Therapeutics.
- Terminated
- Registry status
- 1
- Enrollment target
NCT06140329 is a clinical trial that was terminated before completion, run by PYC Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT06140329 was terminated before completion, sponsored by PYC Therapeutics.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-02-28 |
| Est. Completion | 2025-03-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06140329
The ClinicalTrials.gov registry entry for NCT06140329 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PYC Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06140329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06140329 about?
NCT06140329 is a clinical study titled "Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation". The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.
What is the current status of trial NCT06140329?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2024-02-28. Estimated completion is 2025-03-10.
Who is sponsoring clinical trial NCT06140329?
This trial is sponsored by PYC Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.